These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 17426082

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Endoglin in pregnancy complicated by fetal intrauterine growth restriction in normotensive and preeclamptic pregnant women: a comparison between preeclamptic patients with appropriate-for-gestational-age weight infants and healthy pregnant women.
    Laskowska M, Laskowska K, Oleszczuk J.
    J Matern Fetal Neonatal Med; 2012 Jun; 25(6):806-11. PubMed ID: 21793708
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia.
    Baumann MU, Bersinger NA, Mohaupt MG, Raio L, Gerber S, Surbek DV.
    Am J Obstet Gynecol; 2008 Sep; 199(3):266.e1-6. PubMed ID: 18771978
    [Abstract] [Full Text] [Related]

  • 5. Soluble endoglin in preeclamptic patients with or without HELLP syndrome.
    Hertig A, Fort J, Lefevre G, Chabbert-Buffet N, Uzan M, Rondeau E, Rozenberg P.
    Am J Obstet Gynecol; 2010 Jun; 202(6):594.e1-4. PubMed ID: 20430360
    [Abstract] [Full Text] [Related]

  • 6. Discordant clinical presentations of preeclampsia and intrauterine fetal growth restriction with similar pro- and anti-angiogenic profiles.
    Alahakoon TI, Zhang W, Trudinger BJ, Lee VW.
    J Matern Fetal Neonatal Med; 2014 Dec; 27(18):1854-9. PubMed ID: 24397483
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion.
    Stepan H, Geipel A, Schwarz F, Krämer T, Wessel N, Faber R.
    Am J Obstet Gynecol; 2008 Feb; 198(2):175.e1-6. PubMed ID: 18226617
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia.
    Jeyabalan A, McGonigal S, Gilmour C, Hubel CA, Rajakumar A.
    Placenta; 2008 Jun; 29(6):555-63. PubMed ID: 18462791
    [Abstract] [Full Text] [Related]

  • 11. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
    Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA, CPEP Study Group.
    N Engl J Med; 2006 Sep 07; 355(10):992-1005. PubMed ID: 16957146
    [Abstract] [Full Text] [Related]

  • 12. Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia.
    Rana S, Cerdeira AS, Wenger J, Salahuddin S, Lim KH, Ralston SJ, Thadhani RI, Karumanchi SA.
    PLoS One; 2012 Sep 07; 7(10):e48259. PubMed ID: 23110221
    [Abstract] [Full Text] [Related]

  • 13. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia.
    Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, Thadhani R.
    Hypertension; 2007 Jul 07; 50(1):137-42. PubMed ID: 17515455
    [Abstract] [Full Text] [Related]

  • 14. An analysis on the roles of angiogenesis-related factors including serum vitamin D, soluble endoglin (sEng), soluble fms-like tyrosine kinase 1 (sFlt1), and vascular endothelial growth factor (VEGF) in the diagnosis and severity of late-onset preeclampsia.
    Cim N, Kurdoglu M, Ege S, Yoruk I, Yaman G, Yildizhan R.
    J Matern Fetal Neonatal Med; 2017 Jul 07; 30(13):1602-1607. PubMed ID: 27658884
    [Abstract] [Full Text] [Related]

  • 15. Increased plasma soluble fms-like tyrosine kinase 1 and endoglin levels in pregnancies complicated with preeclampsia.
    Chedraui P, Lockwood CJ, Schatz F, Buchwalder LF, Schwager G, Guerrero C, Escobar GS, Hidalgo L.
    J Matern Fetal Neonatal Med; 2009 Jul 07; 22(7):565-70. PubMed ID: 19350449
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Serum sFlt1:PlGF ratio, PlGF, and soluble endoglin levels in gestational proteinuria.
    Ohkuchi A, Hirashima C, Matsubara S, Suzuki H, Takahashi K, Usui R, Suzuki M.
    Hypertens Pregnancy; 2009 Feb 07; 28(1):95-108. PubMed ID: 19165674
    [Abstract] [Full Text] [Related]

  • 18. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia.
    Masuyama H, Nakatsukasa H, Takamoto N, Hiramatsu Y.
    J Clin Endocrinol Metab; 2007 Jul 07; 92(7):2672-9. PubMed ID: 17426083
    [Abstract] [Full Text] [Related]

  • 19. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies.
    Powers RW, Jeyabalan A, Clifton RG, Van Dorsten P, Hauth JC, Klebanoff MA, Lindheimer MD, Sibai B, Landon M, Miodovnik M, Eunice Kennedy Shriver National Institute of Child Health Human Development Maternal-Fetal Medicine Units Network.
    PLoS One; 2010 Oct 11; 5(10):e13263. PubMed ID: 20948996
    [Abstract] [Full Text] [Related]

  • 20. Soluble endoglin for the prediction of preeclampsia in a high risk cohort.
    Maynard SE, Moore Simas TA, Bur L, Crawford SL, Solitro MJ, Meyer BA.
    Hypertens Pregnancy; 2010 Oct 11; 29(3):330-41. PubMed ID: 20670156
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.